Neurocrine Biosciences : NBIX

All Neurocrine Biosciences Articles

92 Articles

Jon C. Ogg | Oct 18, 2016 at 9:05 AM EDT

Top Analyst Upgrades and Downgrades: Chipotle, IBM, Level 3, Netflix, PayPal, Salesforce and More

The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Chipotle Mexican Grill, IBM, Level 3 Communications, Netflix,…

Lee Jackson | Jun 22, 2016 at 8:25 AM EDT

Biotechs Highlight Jefferies 4 Top Growth Stocks to Buy

Now is the time to look for good growth stocks as the second half of the year could have solid…

Lee Jackson | Jun 2, 2016 at 10:10 AM EDT

3 Analyst Growth Stocks to Buy With Outsized Upside Potential

In a recent research report, Jefferies is out with its top growth stock calls to kick off June, and we…

Jon C. Ogg | May 28, 2016 at 9:40 AM EDT

8 Speculative Biotech and Biohealth Stocks With Major Analyst Upside Calls

Here are seven speculative biotech and biohealth players in which analyst calls during the week ending May 27 have given…

Lee Jackson | May 24, 2016 at 10:05 AM EDT

4 Jefferies Growth Stocks to Buy That Have Big Upside Potential

These four solid growth companies are trading well below recent highs and the Jefferies price targets. With very solid upside…

Jon C. Ogg | May 23, 2016 at 8:55 AM EDT

Top Analyst Upgrades and Downgrades: Alcoa, Boston Scientific, Schlumberger, Sony, Staples and Many More

The top analyst upgrades, downgrades and initiations seen on Monday morning include Alcoa, Boston Scientific, Schlumberger, Sony and Staples.

Lee Jackson | Apr 18, 2016 at 10:20 AM EDT

Biotech and Pharmaceuticals Highlight Jefferies Top Growth Stock Buys

New research from Jefferies highlights this week's top growth stock picks, and there is a clear bias for some top…

Lee Jackson | Apr 5, 2016 at 9:55 AM EDT

3 Hot Biotechs Highlight Jefferies Growth Stocks to Buy This Week

This week's top U.S. growth calls from the analysts at Jefferies focus on companies that have some outstanding upside potential,…

Lee Jackson | Jan 4, 2016 at 10:05 AM EST

Top Biotech Stock Favorites to Buy With Up to 100% Upside Potential

Like others on Wall Street, the analysts at the specialty biotech and health care boutique firm Leerink see 2016 as…

Chris Lange | Oct 8, 2015 at 9:10 AM EDT

Neurocrine Bio Soars on Positive Phase 3 Results

Neurocrine Biosciences made waves in the market on Thursday morning after it announced positive results in a Phase 3 trial.

Lee Jackson | Aug 25, 2015 at 10:05 AM EDT

3 Top Jefferies Growth Stocks to Buy After Sell-Off

In a new report from Jefferies, three top growth stocks hit their screens and they all have substantial upside potential…

Lee Jackson | May 14, 2015 at 9:20 AM EDT

Analyst Issues 5 Potential Biotech Buyout Candidates

Cowen sees the potential for super-mergers in biotech, as well as a large group of smaller targets that may be…

Jon C. Ogg | Mar 19, 2015 at 8:05 AM EDT

Top Analyst Upgrades and Downgrades: Chesapeake, eBay, Enterprise, Gilead, Newmont, Wynn and More

Thursday's top analyst upgrades and downgrades include Chesapeake Energy, eBay, Enterprise Products Partners, Gilead Sciences, Newmont Mining and Wynn Resorts.

Jon C. Ogg | Mar 4, 2015 at 8:55 AM EST

Top Analyst Upgrades and Downgrades: Alcoa, Apache, Bob Evans, F5 Networks, McDonald’s and More

Wednesday's top analyst upgrades, downgrades and initiations includes Alcoa, Apache, Bob Evans, F5, Hain and McDonald's.

Chris Lange | Feb 18, 2015 at 8:50 AM EST

Neurocrine Biosciences Announces New Offering

Neurocrine Biosciences has announced that it will have another public offering of its common stock to raise roughly $225 million.

1 … 3 4 5 6 7

Neurocrine Biosciences : NBIX

All Neurocrine Biosciences Articles

Top Analyst Upgrades and Downgrades: Chipotle, IBM, Level 3, Netflix, PayPal, Salesforce and More

Biotechs Highlight Jefferies 4 Top Growth Stocks to Buy

3 Analyst Growth Stocks to Buy With Outsized Upside Potential

8 Speculative Biotech and Biohealth Stocks With Major Analyst Upside Calls

4 Jefferies Growth Stocks to Buy That Have Big Upside Potential

Top Analyst Upgrades and Downgrades: Alcoa, Boston Scientific, Schlumberger, Sony, Staples and Many More

Biotech and Pharmaceuticals Highlight Jefferies Top Growth Stock Buys

3 Hot Biotechs Highlight Jefferies Growth Stocks to Buy This Week

Top Biotech Stock Favorites to Buy With Up to 100% Upside Potential

Neurocrine Bio Soars on Positive Phase 3 Results

3 Top Jefferies Growth Stocks to Buy After Sell-Off

Analyst Issues 5 Potential Biotech Buyout Candidates

Top Analyst Upgrades and Downgrades: Chesapeake, eBay, Enterprise, Gilead, Newmont, Wynn and More

Top Analyst Upgrades and Downgrades: Alcoa, Apache, Bob Evans, F5 Networks, McDonald’s and More

Neurocrine Biosciences Announces New Offering

Why the Pure Bitcoin-Miner Fund Crushed the Blockchain Basket, Up 184%

Why Age 63 Is the Most Expensive Year to Touch Your IRA (Medicare Looks Back Two Years)

PepsiCo’s $200 Billion Stability Play Is Attracting Dividend Investors

Why Age 63 Is the Most Expensive Year to Touch Your IRA (Medicare Looks Back Two Years)

"100 Million Percent Wrong" Suze Orman Rages At Social Security Expert's "Crazy" Advice

VOO Just Crossed $1 Trillion. Here’s the Hidden Risk Nobody’s Pricing In

Why the Pure Bitcoin-Miner Fund Crushed the Blockchain Basket, Up 184%

Neurocrine Biosciences : NBIX

All Neurocrine Biosciences Articles

Top Analyst Upgrades and Downgrades: Chipotle, IBM, Level 3, Netflix, PayPal, Salesforce and More

Biotechs Highlight Jefferies 4 Top Growth Stocks to Buy

3 Analyst Growth Stocks to Buy With Outsized Upside Potential

8 Speculative Biotech and Biohealth Stocks With Major Analyst Upside Calls

4 Jefferies Growth Stocks to Buy That Have Big Upside Potential

Top Analyst Upgrades and Downgrades: Alcoa, Boston Scientific, Schlumberger, Sony, Staples and Many More

Biotech and Pharmaceuticals Highlight Jefferies Top Growth Stock Buys

3 Hot Biotechs Highlight Jefferies Growth Stocks to Buy This Week

Top Biotech Stock Favorites to Buy With Up to 100% Upside Potential

Neurocrine Bio Soars on Positive Phase 3 Results

3 Top Jefferies Growth Stocks to Buy After Sell-Off

Analyst Issues 5 Potential Biotech Buyout Candidates

Top Analyst Upgrades and Downgrades: Chesapeake, eBay, Enterprise, Gilead, Newmont, Wynn and More

Top Analyst Upgrades and Downgrades: Alcoa, Apache, Bob Evans, F5 Networks, McDonald’s and More

Neurocrine Biosciences Announces New Offering

Why the Pure Bitcoin-Miner Fund Crushed the Blockchain Basket, Up 184%

Why Age 63 Is the Most Expensive Year to Touch Your IRA (Medicare Looks Back Two Years)

PepsiCo’s $200 Billion Stability Play Is Attracting Dividend Investors

Featured Reads

Why Age 63 Is the Most Expensive Year to Touch Your IRA (Medicare Looks Back Two Years)

"100 Million Percent Wrong" Suze Orman Rages At Social Security Expert's "Crazy" Advice